References
- Fuchs CS, et al. Safety and Efficacy of Pembrolizumab Monotherapy in
Patients With Previously Treated Advanced Gastric and Gastroesophageal
Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018
May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May
10. Erratum in: JAMA Oncol. 2019 Apr 1;5(4):579. PMID: 29543932;
PMCID: PMC5885175.
- Shitara K, et al. Efficacy and Safety of Pembrolizumab or
Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients
With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3
Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580.
doi: 10.1001/jamaoncol.2020.3370. PMID: 32880601; PMCID: PMC7489405.
- Swami U, Monga V, Bossler AD, Zakharia Y, Milhem M. Durable Clinical
Benefit in Patients with Advanced Cutaneous Melanoma after
Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse
Events. J Oncol. 2019;2019:1856594. Published 2019 Jul 25.
doi:10.1155/2019/1856594
- Borcoman, E., et al. “Novel Patterns of Response under
Immunotherapy.” Annals of Oncology, vol. 30, no. 3, 2019, pp.
385–396., https://doi.org/10.1093/annonc/mdz003.
- Mulder EEAP, de Joode K, Litière S, Ten Tije AJ, Suijkerbuijk KPM,
Boers-Sonderen MJ, Hospers GAP, de Groot JWB, van den Eertwegh AJM,
Aarts MJB, Piersma D, van Rijn RS, Kapiteijn E, Vreugdenhil G, van den
Berkmortel FWPJ, Hoop EO, Franken MG, Ryll B, Rutkowski P, Sleijfer S,
Haanen JBAG, van der Veldt AAM. Early discontinuation of PD-1 blockade
upon achieving a complete or partial response in patients with
advanced melanoma: the multicentre prospective Safe Stop trial. BMC
Cancer. 2021 Mar 25;21(1):323. doi: 10.1186/s12885-021-08018-w. PMID:
33765967; PMCID: PMC7993897.
- Passarelli, Anna et. al. “Immune system and melanoma biology: a
balance between immunosurveillance and immune escape.”Oncotarget vol. 8,62 106132-106142. 31 Oct. 2017,
doi:10.18632/oncotarget.22190
- Abou-Alfa, G. K., et. al. (2022). Phase 3 randomized, open-label,
Multicenter Study of Tremelimumab (T) and durvalumab (D) as first-line
therapy in patients (PTS) with unresectable hepatocellular carcinoma
(uHCC): Himalaya. Journal of Clinical Oncology,40(4_suppl), 379–379.
https://doi.org/10.1200/jco.2022.40.4_suppl.379
- Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J.,
Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin,
J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C.,
Shapira-Frommer, R., Kosh, M., Zhou, H., … Ribas, A. (2015).
Pembrolizumab versus Ipilimumab in advanced melanoma. New
England Journal of Medicine, 372(26), 2521–2532.
https://doi.org/10.1056/nejmoa1503093
- Mulder, E.E.A.P., de Joode, K., Litière, S. et al. Early
discontinuation of PD-1 blockade upon achieving a complete or partial
response in patients with advanced melanoma: the multicentre
prospective Safe Stop trial. BMC Cancer 21, 323 (2021).https://doi.org/10.1186/s12885-021-08018-w
- Pons-Tostivint, E., Latouche, A., Vaflard, P., Ricci, F., Loirat, D.,
Hescot, S., Sablin, M.-P., Rouzier, R., Kamal, M., Morel, C., Lecerf,
C., Servois, V., Paoletti, X., & Le Tourneau, C. (2019). Comparative
analysis of durable responses on immune checkpoint inhibitors versus
other systemic therapies: A pooled analysis of phase III trials.JCO Precision Oncology, (3), 1–10.
https://doi.org/10.1200/po.18.00114
- Waterhouse, D. M., Garon, E. B., Chandler, J., McCleod, M., Hussein,
M., Jotte, R., Horn, L., Daniel, D. B., Keogh, G., Creelan, B.,
Einhorn, L. H., Baker, J., Kasbari, S., Nikolinakos, P., Babu, S.,
Couture, F., Leighl, N. B., Reynolds, C., Blumenschein, G., …
Spigel, D. R. (2020). Continuous versus 1-year fixed-duration
nivolumab in previously treated advanced non–small-cell lung cancer:
Checkmate 153. Journal of Clinical Oncology, 38(33),
3863–3873. https://doi.org/10.1200/jco.20.00131
- Zhang, Yuanyuan, and Zemin Zhang. “The history and advances in cancer
immunotherapy: understanding the characteristics of tumor-infiltrating
immune cells and their therapeutic implications.” Cellular &
molecular immunology vol. 17,8 (2020): 807-821.
doi:10.1038/s41423-020-0488-6
- Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S,
Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M,
Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN,
Zippelius A. A transcriptionally and functionally distinct PD-1+ CD8+
T cell pool with predictive potential in non-small-cell lung cancer
treated with PD-1 blockade. Nat Med. 2018 Jul;24(7):994-1004. doi:
10.1038/s41591-018-0057-z. Epub 2018 Jun 11. PMID: 29892065; PMCID:
PMC6110381.
- A.C. Tan, L. Emmett, S. Lo, V. Liu, R. Kapoor, M.S. Carlino, A.D.
Guminski, G.V. Long, A.M. Menzies. FDG-PET response and outcome from
anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, Volume
29, Issue 10, 2018. Pages 2115-2120.
https://doi.org/10.1093/annonc/mdy330.
- O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, J.D.
Wolchok, P. Hersey, R. Joseph, J.S. Weber, R. Dronca, T.C. Mitchell,
A. Patnaik, H.M. Zarour, A.M. Joshua, Q. Zhao, E. Jensen, S. Ahsan, N.
Ibrahim, A. Ribas. Five-year survival outcomes for patients with
advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of
Oncology, Volume 30, Issue 4, 2019.https://doi.org/10.1093/annonc/mdz011.
- Cost info & financial help. Cost Information and Financial
Help With KEYTRUDA® (pembrolizumab) | Patients. (n.d.).
Retrieved November 18, 2022, from
https://www.keytruda.com/financial-support/
- Pricing information. Cost & Pricing Information |
OPDIVO® (nivolumab) and OPDIVO-based Combinations. (n.d.). Retrieved
November 18, 2022, from https://www.bmspricinginformation.com/opdivo